HSP90 inhibitor (IPI-504) is known to repress the mutant p53 aggregates in both SK-BR-3 (containing p53 R175H) and BT-549 (containing p53 R249S) breast cancer cell lines, which have high BAG2 expression [17]. Here, TP53 is linked to breast carcinoma.